English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE:DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million.
Preliminary cell engineering and biosecurity revenue are expected to be within the disclosed guidance range of $145 million-$150 million and up to $110 million in 2023, respectively.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
